Top

Published in:

2017 | OriginalPaper | Chapter

1. Introduction

Authors : Naitee Ting, Ding-Geng Chen, Shuyen Ho, Joseph C. Cappelleri

Published in: Phase II Clinical Development of New Drugs

Publisher: Springer Singapore

Activate our intelligent search to find suitable subject content or patents.

search-config

AI-assisted search

Off

Abstract

Most of the drugs available in pharmacy started out as a chemical compound or a biologic discovered in laboratories.

Dont have a licence yet? Then find out more about our products and how to get one now:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

inform now

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 340 Zeitschriften

aus folgenden Fachgebieten:

Bauwesen + Immobilien
Business IT + Informatik
Finance + Banking
Management + Führung
Marketing + Vertrieb
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

inform now

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 390 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Maschinenbau + Werkstoffe

Jetzt Wissensvorsprung sichern!

inform now

next chapter Concept of Alpha

Cappelleri, J. C., & Spielberg, S. P. (2015). Advances in clinical outcome assessments. Therapeutic Innovation & Regulatory Science, 49, 780–782.CrossRef

Cappelleri, J. C., Zou, K. H., Bushmakin, A. G., Alvir, J. M. J., Alemayehu, D., & Symonds, T. (2013). Patient-reported outcomes: Measurement, implementation and interpretation. Boca Raton, Florida: Chapman & Hall/CRC Press.

Chow, S. C., & Liu, J. P. (1999). Design and analysis of bioavailability and bioequivalence studies. New York: Marcel Dekker, Inc.MATH

Crowley, J., & Hoering, A. (2012). Handbook of statistics in clinical oncology (3rd ed.). Boca Raton, FL: Chapman & Hall/CRC Press.

Doward, L.C., Gnanasakthy, A., & Baker, M.G. (2010). Patient reported outcomes: Looking beyond the claim. Health and Quality of Life Outcomes, 8, 89 (Open access).

Drummon, M. F., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. (2005). Methods for the economic evaluation of health care programmes (3rd ed.). New York, NY: Oxford University Press.

European Medicines Agency (EMA) & Committee for medicinal products for human use. (2005). Reflection paper on the regulatory guidance for us of health-related quality of life (HRQOL) measures in the evaluation of medicinal products. European Medicines Agency. www.emea.europa.eu/pdfs/human/ewp/13939104en.pdf.

European Medicines Agency (EMA) & Committee for medicinal products for human use. (2009). Qualification of novel methodologies for drug development: Guidance to applicants. European Medicines Agency. www.ema.europa.eu/pdfs/human/biomarkers/7289408en.pdf.

Fairclough, D. L. (2004). Patient reported outcomes as endpoints in medical research. Statistical Methods in Medical Research, 13, 115–138.CrossRefMATHMathSciNet

Fairclough, D. L. (2010). Design and analysis of quality of life studies in clinical trials (2nd ed.). Boca Raton, Florida: Chapman & Hall/CRC.MATH

Finney, D. J. (1978). Statistical methods in biological assay (3rd ed.). London: Charles Griffin.MATH

Food and Drug Administration (FDA). (2009). Guidance for industry on patient-reported outcome measures: Use in medical product development to support labeling claims. Federal Register, 74(235), 65132–65133. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/ucm284399.htm

Food and Drug Administration (FDA). (2010). Draft guidance for industry on qualification process for drug development tools. Federal Register, 75(205), 65495–65496. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/ucm284399.htm

Glick, H. A., Doshi, J. A., Sonnad, S. S., & Polsky, D. (2005). Economic evaluation in clinical trials (2nd ed.). New York, NY: Oxford University Press.

Green, S., & Benedetti, J. (2012). Clinical trials in oncology (3rd ed.). Boca Raton, FL: Chapman & Hall/CRC Press.

ICH-E4. (1994). Harmonized tripartite guideline dose-response information to support drug registration.

Morrow, T. (2004). Defining the difference: What makes biologics unique. Biotechnology Healthcare, 24–29.

Muenning, P. (2007). Cost-effectiveness analysis in health: A practical approach (2nd ed.). San Francisco, California: Jossey-Bass.

Selwyn, M.R. (1988). Preclinical safety assessment. In K.E. Peace (Ed.), Biopharmaceutical statistics for drug development. New York: Marcel Dekker, Inc.

Ting, N. (2003). Drug development, encyclopedia of biopharmaceutical statistics (2nd ed., pp. 317–324). Marcel Dekker.

Ting, N. (2006). Introduction and drug development process, dose finding in drug development (pp. 1–17). New York: Springer.

Title: Introduction
Authors: Naitee Ting
Ding-Geng Chen
Shuyen Ho
Joseph C. Cappelleri
Publisher: Springer Singapore
Book: Phase II Clinical Development of New Drugs
Print ISBN: 978-981-10-4192-1

Electronic ISBN: 978-981-10-4194-5

Copyright Year: 2017
DOI: https://doi.org/10.1007/978-981-10-4194-5_1

Springer Professional

Abstract

Please log in to get access to your license.

Dont have a licence yet? Then find out more about our products and how to get one now:

Springer Professional "Wirtschaft+Technik"

Springer Professional "Wirtschaft"

Springer Professional "Technik"

Premium Partner